Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (144)	8/18/1998 9:45:00 PM
From: Abuckatatime	Respond to of 626

Richard, So you think they may be defying the laws of gravity over in Kentucky huh? Validation by other researchers would be welcome(if indeed such doesn't already exist). I'll list the articles by Foon et al cited in the letter in Nat Med. for anyone interested in reading further about this team's anti-id work. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disaloganglioside GD2. Clin. Cancer Res. 4, 1117-1124 (1998). Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin.Cancer Res. 3, 1267-1276 (1997). Immune responses in patients with cutaneous T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted Tcell antigen. Clin.Cancer Res 1, 1285-1294 (1995). Active immunity to the carcioembryonic antigen in patients treated with an anti-idiotype antibody vaccine. J Clin. Invest. 96, 334-342 (1995).